R(+)PPX High Dose Treatment of ALS

• Status: Completed
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: All

Summary

R(+)pramipexole is administered in escalating doses to patients with early ALS. Plasma and spinal fluid levels of R(+)PPX are monitored, in addition to biochemical markers of oxidative stress.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bennett, James P., Jr., M.D., Ph.D.
• Treatments: Pramipexole

Criteria

Inclusion Criteria:

• definite ALS no prior exposure to R(+)PPX

Exclusion Criteria:

• ALSFRS at baseline <40 FVC at baseline <70%